Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. It functions by disrupting the proteasome's ability to degrade ubiquitinated proteins, leading to an accumulation of proteins within the cell, causing apoptosis, especially in rapidly dividing cancer cells.
